RxDoctor Payments Data

Birju Bhatt, MD

Rheumatology · Wilkes Barre, PANPI 1881912236

Payments from drug & device makers

$2,084in general payments, 2019–2025

Across 43 payments — averaging $48.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$517
  • Novartis$459
  • Amgen$366
  • Sanofi-aventis U.S. LLC$249
  • Johnson & Johnson$234
  • UCB, Inc.$92
  • plus $167 from 4 others

What the payments were for

  • Food & beverage$1,88891%
  • Education$1969%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,084 in reported general payments places this provider in the 45th percentile of 351 rheumatology providers in Pennsylvania.

See all rheumatology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$52,203
Medicare patients
256
Services billed
760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab119$887,771
Enbrel SureclickEtanercept65$456,936
XeljanzTofacitinib Citrate36$200,808
Cosentyx Sensoready (2 Pens)Secukinumab21$192,667
RinvoqUpadacitinib25$164,504
Humira(Cf) PenAdalimumab19$126,772
Xeljanz XrTofacitinib Citrate19$108,763
OtezlaApremilast20$93,990
Taltz AutoinjectorIxekizumab12$89,071
TymlosAbaloparatide31$84,087
Cimzia (2 Pack)Certolizumab Pegol14$79,099
KevzaraSarilumab11$47,726
ActemraTocilizumab13$41,313
Hydroxychloroquine Sulfate315$10,403
MethotrexateMethotrexate Sodium240$6,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$90$200,80836 claims
AbbVieRinvoq$517$164,50425 claims
AmgenOtezla$366$93,99020 claims
UCB, Inc.Cimzia (2 Pack)$92$79,09914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 351 rheumatology providers in Pennsylvania.

Other rheumatology in Wilkes Barre

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →